Publication Cover

American Journal of Respiratory and Critical Care Medicine

Publishes the most innovative research, highest quality reviews, clinical trials, guidelines, and statements in pulmonary, critical care, and sleep-related fields

Blue Briefing

In this installment of Blue Briefing, we look at Liam Heaney and colleagues' paper "Remotely Monitored Therapy and Nitric Oxide Suppression Identifies Nonadherence in Severe Asthma", published in the February 15, 2019 asthma issue of the Blue Journal.

Current Issue Highlights

Some of the objectives of this review are to summarize the current understanding of the role ECLS may play in minimizing VILI; suggest best practice mechanical ventilation strategies during ECLS, given the existing data; and describe the interplay between ECLS, gas exchange, and ventilator parameters..
MARCH 1, 2020 AJRCCM
In this integrative deep sequencing study of SERPINA1 with alpha-1 antitrypsin concentrations in a heavy smoker and chronic obstructive pulmonary disease cohort, the authors confirmed the effects of PI Z heterozygote and compound heterozygote genotypes.
MARCH 1, 2020 AJRCCM
This study provides new genetic evidence for the association of GDF2 mutations with PAH and confirms that these mutations cause impaired BMP9 function and signaling. It shows for the first time that BMP10 levels are altered in PAH and demonstrates biological integration of plasma BMP9 and BMP10 levels.
MARCH 1, 2020 AJRCCM

Journal Metrics

Impact Factor
16.494
Google h5-index 108
Full-Text Views
6.5 Million
Acceptance Rate
9%
Time to First Decision
17 Days
More Metrics

Out of the Blue

News & Announcements

ATS Partners with AJE to Provide More Author Services
Enhance your research with the help of dedicated experts. Premiere manuscript editing services, unlimited re-edits, poster creation, abstracts, videos, and more.
New Video Feature: Blue Briefing!
We're excited to announce the release of our newest video feature: Blue Briefing! In our inaugural episode we highlight the comparison of outcomes in patients 65-74 years old from SEER-Medicare and NLST datasets in stage I lung cancer.
AJRCCM New Impact Factor
AJRCCM is proud to announce our new Impact Factor of 16.494!